A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

Memorial Sloan-Kettering Cancer Center, New York

Roswell Park Cancer Institute, Buffalo

UPMC Cancer Pavilion, Pittsburgh

Georgetown University Hospital, Washington D.C.

University of Maryland, Greenebaum Cancer Center, Baltimore

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Weinberg Cancer Institute, Baltimore

Virginia Cancer Specialists, Fairfax

Oncology and Hematology Associates of Southwest Virginia Inc., Blacksburg

Greenville Health System, Clinical Research Unit, Institute for Translational Oncology Research, Greenville

Piedmont Cancer Institute, Atlanta

Georgia Cancer Specialists, PC, Atlanta

Sarah Cannon, Fort Myers

Ocala Oncology Center, PL, Ocala

The Sarah Cannon Research Institute, Nashville

Tennessee Oncology, PLLC, Chattanooga

Norton Cancer Institute, Louisville

Case Western Reserve University, Cleveland

Oncology Hematology Care, Inc., Cincinnati

University of Michigan Medical Center, Clinical Trials Office, Ann Arbor

Karmanos Cancer Institute, Detroit

Minnesota Oncology Hematology , P.A., Minneapolis

Univeristy of Chicago Medical Center, Chicago

Oncology Hematology West PC, dba Nebraska Cancer Specialists, Omaha

Highlands Oncology Group, Rogers

Texas Oncology, P.A., Dallas

Texas Oncology-Bedford, Bedford

The University of Texas MD A nderson Cancer Center, Houston

Cancer Care Network of South Texas, San Antonio

Texas Oncology-South Austin, Austin

Rocky Mountain Cancer Centers, Denver

Cedars-Sinai Medical Center, Los Angeles

Providence Cancer Center Oncology and Hematology Care Eastside, Portland

Swedish Cancer Institute, Seattle

Yale University, New Haven